Draft guidance clarifies FDA's expectations for SPAs

FDA issued new draft guidance on procedures and policies for obtaining a special protocol assessment agreement. The new guidance adds significantly more details compared to the agency's 2002 guidance on the topic.

The new guidance formally adds the agency's thinking on protocols supporting approval of a biosimilar, as well as animal rule efficacy protocols. Both additions reflect laws enacted since the previous guidance. ...